Navigation Links
New Approach to Treating Anthrax Significantly Improves Survival Rates in Pivotal Efficacy Studies
Date:12/18/2007

a single high dose of ABthrax

survived (p=0.0007 vs. placebo).

-- 50 percent of those that received a low dose survived (p=0.0064 vs.

placebo).

-- None of the monkeys in the placebo control group survived.

A separate study that measured 14-day survival in rabbits also demonstrated a statistically significant survival benefit versus placebo. All ABthrax-treated animals that survived in both studies were rapidly cleared of anthrax toxin and bacteria following intravenous administration of a single dose of ABthrax. In contrast, all placebo-treated animals remained bacteremic or toxemic and died.

HGS also reported today that it has completed the second safety study of ABthrax in human volunteers, bringing the total number of people who have participated in human safety trials to more than 180. The clinical results to date suggest that ABthrax was generally safe and well tolerated. In addition, the new study demonstrated that co-administration of ABthrax with the antibiotic Cipro (ciprofloxacin) did not affect the pharmacokinetics of either Cipro or ABthrax, and suggested that ABthrax can be administered in combination with antibiotics. This is a key finding given the important role that antibiotics are expected to continue to play in the treatment of anthrax disease.

The Need for New Means to Fight Anthrax Infections

Two options are currently available for the prevention or treatment of anthrax infections -- a vaccine and antibiotics. Both are essential to dealing with anthrax, but both have limitations. The anthrax vaccine takes several weeks following the initial doses before immunity is detectable, and requires multiple injections over a period of eighteen months, in addition to annual booster vaccination, to maintain protective immunity. Antibiotics are effective in killing anthrax bacteria, but are not effective against the anthrax toxins once those toxins have been released into the blood. Antibiotics also
'/>"/>

SOURCE Human Genome Sciences, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Study Demonstrates Mindful Approach to Aging
2. Hillary Clinton Pledges Bold Approach to Stopping HIV/AIDS & Global Poverty
3. Raydiance Collaborates With Rutgers University and Nations Largest Tissue Bank to Develop Innovative Tissue Processing Approaches
4. Endoscopy Identified as Safe and Effective Method in Treating Common Complication of Gastric Bypass Surgery
5. New Data Show Doripenem as Effective as Commonly Used Therapies in Treating Hospital-Acquired Pneumonias
6. New Data Show Ceftobiprole as Effective as Combination Therapy in Treating Patients With Complicated Skin Infections, Including MRSA
7. European Unions CHMP Issues Positive Opinion on PEGINTRON(TM) Combination Therapy for Retreating Hepatitis C Patients Who Failed Previous Therapy
8. Promising Results in Treating Facial Bruising From Injectables
9. Evidence of Benefit Lacking for Many Common Ways of Treating Osteoarthritis of the Knee
10. New Data Show Ceftobiprole as Effective as Combination Therapy in Treating Patients with Diabetic Foot Infections
11. Edwards Resilient Trial Demonstrates Statistically Superior Results for Treating Peripheral Arterial Disease in the Leg
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... Va. , Aug. 27, 2015  The ... the Food and Drug Administration,s (FDA,s) draft guidance ... reference products and biosimilars, to bear a nonproprietary ... AMCP has been seeking a decision from the ... 18 diverse health care stakeholders urging the agency ...
(Date:8/27/2015)... Biosimilars are not generics and the ... and Drug Administration (FDA) for recognizing that each ... guidance issued today. The FDA,s draft guidance on ... calling for biological products to bear a nonproprietary ... reflects the agency,s thinking that "there is a ...
(Date:8/27/2015)... INDIANAPOLIS , Aug. 27, 2015  Eli Lilly ... Morgan Stanley Global Healthcare Conference on Thursday, September 17, ... and president of Lilly Oncology and Richard Gaynor ... medical affairs for Lilly Oncology, will participate in a ... A live audio webcast will be available ...
Breaking Medicine Technology:AMCP Is Disappointed in FDA's Draft Guidance and Proposed Rule Calling for Suffix on Nonproprietary Names of Biological Products 2Biologics Prescribers Collaborative (BPC) Statement on FDA Draft Guidance entitled "Nonproprietary Naming of Biological Products" 2Lilly to Participate in Morgan Stanley Global Healthcare Conference 2
... , VIENNA, Va., Jan. 11 CEL-SCI Corporation ... a developer of vaccines and therapeutics for the prevention and ... validation of all critical utilities and manufacturing equipment at its ... represents a very important milestone as it allows CEL-SCI to ...
... SANTA MONICA, Calif., Jan. 11 Derycz Scientific (OTC Bulletin Board: ... the flow of information from content publishers to enterprise customers and ... 2010, on the website of DDN ( Drug Discovery ... Peter Derycz, is titled "Speeding the Path to FDA Approval in ...
Cached Medicine Technology:CEL-SCI Completes Validation of Manufacturing Facility Allowing It To Commence Manufacturing of Multikine 2CEL-SCI Completes Validation of Manufacturing Facility Allowing It To Commence Manufacturing of Multikine 3CEL-SCI Completes Validation of Manufacturing Facility Allowing It To Commence Manufacturing of Multikine 4Derycz Scientific Featured In DDN (Drug Discovery News) 2Derycz Scientific Featured In DDN (Drug Discovery News) 3
(Date:8/28/2015)... ... August 28, 2015 , ... The Kentucky State Department of Workforce Investment Commissioner ... they are applying for, they are unable to pass the initial drug test and ... testing policies in order to be able to hire long-term, skilled talent. (1) Will ...
(Date:8/28/2015)... Dallas, TX (PRWEB) , ... August 28, 2015 , ... ... Surgical Center is taking part with their subsidiary USPI Tenet Health. , The American ... to fight heart disease and stroke. They believe that together, a difference can be ...
(Date:8/28/2015)... ... , ... The 6th Annual Survivor in the City, Chicago silent auction ... accolade to its cadre of widespread support—an official letter of support and gratitude from ... medical community and the University of Illinois at Chicago’s Department of Neurosurgery, the Brain ...
(Date:8/28/2015)... ... August 28, 2015 , ... Saint Petersburg, FL ... with zero fat, carbs, sugar, gluten, lactose or caffeine in a convenient 2 ... 2015 SupplySide CPG Editor’s Choice Awards. , Five consumer packaged goods (CPG) products ...
(Date:8/28/2015)... , ... August 28, 2015 , ... ... nationwide. Addictions specialist, Dr. James Strawbridge, gives a new approach on solutions in ... should begin with the employer and employees getting together for meaningful group meetings. ...
Breaking Medicine News(10 mins):Health News:Hiring Obstacles: Drug Abuse a Problem for Workforce 2Health News:Hiring Obstacles: Drug Abuse a Problem for Workforce 3Health News:Hiring Obstacles: Drug Abuse a Problem for Workforce 4Health News:North Central Surgical Center’s Subsidiary Participates in Walk 2Health News:Chicago Mayor Pens Official Support of Annual Survivor in the City Event Benefitting Brain Aneurysm Foundation 2Health News:Chicago Mayor Pens Official Support of Annual Survivor in the City Event Benefitting Brain Aneurysm Foundation 3Health News:Pocket Protein™ Named 2015 CPG Editor’s Choice Award Finalist by Informa’s SupplySide 2Health News:Pocket Protein™ Named 2015 CPG Editor’s Choice Award Finalist by Informa’s SupplySide 3
... Ended 2007, BANGOR, Maine, Oct. 15 Nyer Medical ... results for its,fiscal year ended June 30, 2007. Revenues increased ... compared to $63,596,975 as reported for,the same period ended June ... $.02 basic net earnings per common share for the year ...
... centers did as well, 266,604 fewer patients would die ... -- Patients in the top-ranked hospitals in the United ... those in the lowest-rated hospitals, according to a new ... 10th annual HealthGrades Hospital Quality in America Study looked ...
... mechanisms involved in resistance to treatment of breast cancer ... Press in the October issue of the journal ... identify patients who are unlikely to respond to trastuzumab ... patients. , Trastuzumab is an antibody used as a ...
... FORT WORTH, Texas, Oct. 15 DSS Research asked ... around PFFS sales,practices in their June Senior Trax(TM) survey. ... Medicare eligibles. Overall, 13.3% said they,had heard or read ... past two months. This figure ranged from a high ...
... Nine of Texas, 181,legislators are being honored ... of their accomplishments on behalf of health care,during ... Texas Hospital,Association created the award in 1997 to ... outstanding leadership on issues important,to hospitals and health ...
... NEW YORK, Oct. 15 L,Oreal Paris, the worldwide ... Mexoryl SX (ecamsule), a new daily moisturizer with advanced ... rays -- the number,one cause of skin aging. After ... exclusive to L,Oreal, has been,approved in a formula by ...
Cached Medicine News:Health News:Nyer Medical Group, Inc. Reports EPS of $.02 on Record Revenues of $69.9 Million for Fiscal Year Ended 2007 2Health News:Nyer Medical Group, Inc. Reports EPS of $.02 on Record Revenues of $69.9 Million for Fiscal Year Ended 2007 3Health News:Nyer Medical Group, Inc. Reports EPS of $.02 on Record Revenues of $69.9 Million for Fiscal Year Ended 2007 4Health News:America's Top Hospitals Are Real Lifesavers 2Health News:Genetic approach provides new insight into trastuzumab resistance in breast cancer 2Health News:THA Honors Nine Legislators for Contributions to Health Care 2Health News:Video: New FDA-Approved Sun Protectant Saves Skin All Year Round 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: